Porton Pharma Solutions Ltd(300363) 3 on the evening of March 25, the annual report of 2021 was released. In 2021, the company achieved an operating revenue of 3.105 billion yuan, a year-on-year increase of 49.87%; The net profit attributable to the shareholders of the listed company was 524 million yuan, a year-on-year increase of 61.49%; The basic earnings per share is 0.97 yuan. The company plans to distribute a cash dividend of 1.93 yuan (including tax) to all shareholders for every 10 shares.
At present, it has three major cdmo R & D centers in Chengdu, cdmo , cdmo in New Jersey and cdmo in Shanghai.
The annual report shows that in 2021, the company’s operating revenue reached a record high, and the revenue contribution mainly came from the cdmo business of API in the core business segment, realizing an operating revenue of 3.069 billion yuan, a year-on-year increase of 51%. The cdmo business of preparations has achieved a breakthrough of “from 0 to 1” and achieved an operating revenue of RMB 2016 million. Cdmo business of gene cell therapy achieved an operating revenue of 13.87 million yuan, an increase of 897% over the same period of last year. From the perspective of customers’ location, the European market, as the company’s largest market, increased its operating revenue by 40% year-on-year in 2021; The second and third largest markets are North America and China respectively. During the reporting period, the operating revenue increased significantly by 71% and 110% year-on-year respectively.
As the company’s strategic new business, the company’s preparation cdmo business and gene cell therapy cdmo business are still in the period of capacity-building, although they have begun to realize revenue in 2021. During the reporting period, the two new businesses reduced the net profit of the company’s consolidated statements by 106 million yuan. In addition, during the reporting period, the three participating companies in the company’s strategic layout were still in the loss stage, reducing the net profit of the company’s consolidated statements by 31 million yuan. Excluding the above effects, in 2021, the company realized a net profit attributable to shareholders of listed companies of 661 million yuan, an increase of about 80% year-on-year.
On the same day, the company released the performance forecast for the first quarter of 2022. The company expects to achieve an operating revenue of 1.357 billion yuan – 1.466 billion yuan from January to March 2022, with a year-on-year increase of 150% – 170%; It is expected to realize the net profit attributable to the shareholders of the listed company of RMB 326 million to RMB 344 million, with a year-on-year increase of 270% – 290%. For the reasons for performance changes, the announcement shows that benefiting from the continued high prosperity of the cdmo industry, the company’s customer pipeline and product pipeline continue to expand and enrich. In the first quarter of 2022, the company’s orders on hand increased strongly, and the major orders received by the company in the early stage were delivered smoothly in succession during the reporting period.
